Brief: Targovax Oncos-102 Mesothelioma 24-Month Data Shows Class-Leading Median Overall Survival

Circio Holding ASA

10/06/2021 12:25

June 10 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX'S ONCOS-102 MESOTHELIOMA 24-MONTH DATA SHOWS
CLASS-LEADING MEDIAN OVERALL SURVIVAL
    * MEDIAN OVERALL SURVIVAL FOR FIRST-LINE TREATMENT WITH
ONCOS-102
PLUS CHEMOTHERAPY WILL BE BETWEEN 21.9 AND 25.0 MTHS, COMPARED
WITH MOS OF 13.5 MTHS IN CHEMOTHERAPY-ONLY CONTROL GROUP

Source text for Eikon:  ID:nWkrsGQSM 
Further company coverage:  TRVX.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))